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Bodo Laube,² Hirokazu Hirai,²³ Mike Sturgess,* stimulation resulting in high Ca21 influx causes neuronal
cell death in ischemia and other neurodegenerative dis-Heinrich Betz, and Jochen Kuhse
orders (Choi, 1988). Third, simultaneous binding of glu-Department of Neurochemistry
tamate and the coagonist glycine is required for efficientMax-Planck-Institute for Brain Research
activation of NMDA receptors (Johnson and Ascher,Deutschordenstrabe 46
1987; Kleckner and Dingledine, 1988). The mechanism60528 Frankfurt
of coagonist action is not entirely clear but may involveFederal Republic of Germany
allosteric modulation of agonist binding affinities (Mayer*Symphony Pharmaceuticals Inc.
et al., 1989). Pharmacological and electrophysiologicalFrazer, Pennsylvania 19355
studies indicate that glutamate and glycine occupy dis-
tinct sites of the receptor protein (Reynolds et al., 1987;
Henderson et al., 1990).Summary
Molecular studies have shown that NMDA receptors
are oligomeric membrane proteins composed of homol-NMDA receptors require both L-glutamate and the co-
ogous NMDAR1 (NR1) and NR2 subunits (reviewed byagonist glycine for efficient channel activation. The
Hollmann and Heinemann, 1994). The NR1 and NR2 sub-glycine binding site of these heteromeric receptor pro-
units are synthesized as precursor proteins with a cleav-teins is formed by regions of the NMDAR1 (NR1) sub-
able leader sequence followed by a long N-terminalunit thatdisplay sequence similarity to bacterial amino
extracellular domain and, in the second half of the poly-acid binding proteins. Here, we demonstrate that the
peptides, four hydrophobic membrane segments (M1±glutamate binding site is located on the homologous
M4). The M1, M3, and M4 segments are transmembraneregions of the NR2B subunit. Mutation of residues
spanning, whereas segment M2 is thought to form awithin the N-terminal domain and the loop region be-
reentrant loop (Hollmann and Heinemann, 1994; Bennetttween membrane segments M3 and M4 significantly
and Dingledine, 1995; Wo and Oswald, 1994; Hirai et al.,reduced the efficacy of glutamate, but not glycine, in
1996) that lines the ion channel (Kuner et al., 1996).channel gating. Some of the mutations also decreased
The NR1 subunit is expressed in several distinct spliceinhibition by the glutamate antagonists, D-AP5 and
variants throughout the central nervous system (DurandR-CPP. Homology-based molecular modeling of the
et al., 1992; Nakanishi et al., 1992; Sugihara et al., 1992;glutamate and glycine binding domains indicates that
Hollmann et al., 1993). The NR2 subunit exists in fourthe NR2 and NR1 subunits use similar residues to li-
isoforms encoded by different genes (NR2A-D), whichgate the agonists' a-aminocarboxylic acid groups,
create further functional and regional heterogeneity ofwhereas differences in side chain interactions and size
NMDA receptors (Kutsuwada et al., 1992; Meguro et al.,of aromatic residues determine ligand selectivity.
1992; Monyer et al., 1992). Heterologous expression in
Xenopus laevis oocytes has suggested that the NR1
Introduction subunit can form channels that are activated upon coap-
plication of glutamate and glycine (Moriyoshi et al., 1991;
Glutamate, the major excitatory neurotransmitter in the Durand et al., 1992). However, in mammalian cell lines,
vertebrate central nervous system, exerts its postsynap- functional channels are not detected upon expression
tic actions via a diverse set of membrane receptors. Of of NR1 alone (Grimwood et al., 1995; McIlhinney et al.,
these, the ionotropic N-methyl-D-aspartic acid (NMDA) 1996). Coexpression of the NR1 and an NR2 subunit, in
receptors have gained particular attention because of contrast, reproducibly creates large current responses
their crucial roles in brain development, synaptic plastic- in both expression systems (Kutsuwada et al., 1992;
ity, memory formation, and neurotoxicity (Olney, 1990; Meguro et al., 1992; Monyer et al., 1992). This is consis-
Nakanishi, 1992). NMDA receptors display a number tent with a hetero-oligomeric structure of NMDA re-
of unique properties that distinguish them from other ceptors.
ligand-gated ion channels. First, NMDA receptor chan- Site-directed mutagenesis has identified determi-
nels are blocked by extracellular Mg21 at resting mem- nants of glycine binding in distinct regions of the NR1
brane potential and open only upon simultaneous depo- subunit (Kuryatov et al., 1994; Wafford et al., 1995; Hirai
larization and agonist binding (Mayer et al., 1984). et al., 1996). Their localization is consistent with a model
Second, NMDA receptor channels are highly permeable of the glycine-binding pocket, in which the coagonist is
to monovalent ions and Ca21 (Mayer and Westbrook, bound by a ªVenus' flytrapº mechanism between two
1987). NMDA receptor-mediated Ca21 entry triggers domains formed by a sequence preceding the first mem-
important cellular processes, including changes in syn- brane segment M1 and the loop separating membrane
aptic efficacy, such as long-term potentiation and het- segments M3 and M4, respectively (Kuryatov et al.,
erosynaptic depression (Madison, 1991), and prolonged 1994; Hirai et al., 1996). Interestingly, these regions of
glutamate receptor proteins display significant se-
quence similarity with a family of bacterial amino acid±²These authors contributed equally to this work.
binding proteins (Nakanishi et al., 1990; O'Hara et al.,³Present address: Laboratory for Synaptic Function, Frontier Re-
1993), suggesting that a phylogenetically conservedsearch Program, The Institute for Physical and Chemical Research
RIKEN, Wako, Saitana 351±01, Japan. amino acid±binding fold (Oh et al., 1993) creates the
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Figure 1. Partial Alignments of NMDA Receptor Subunit Homology Regions with LAOBP
Regions of the NR2B subunit (Kutsuwada et al., 1992) are aligned with the corresponding sequences of NR1 (Moriyoshi et al., 1991) and the
bacterial periplasmic protein LAOBP (Kang et al., 1991). Identical residues are indicated by black boxes, and isofunctional residues are denoted
by gray boxes. Amino acid substitutions of NR2B are indicated above the alignment, and residues of LAOBP crucial for ligand binding are
given below the respective sequence. The relative positions of the identified binding motifs are shown in a schematic representation of the
NR2B polypeptide. The positions of the first residue of each partial sequence are indicated.
binding pocketsof diverse types of glutamate receptors. AMPA±kainate receptors (reviewed by Wo and Oswald,
1995) and the NR1 subunit (Hirai et al., 1996). The mutantIndeed, swapping of the respective domains has al-
lowed to inverse the pharmacology of recombinant NR2B subunits then were coexpressed with the NR1
subunit in Xenopus laevis oocytes, and dose-responsea-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA) and kainate receptor proteins (Stern-Bach et relations for glycine and glutamate were established by
voltage-clamp recording.al., 1994). In addition, expression of soluble fusion con-
structs encompassing these regions of the GluR2 and As shown in Figure 2, ion flux through the NR1±NR2B
wild-type receptor in the presence of a saturating con-GluR4 glutamate receptor subunits in eukaryotic cells
or bacteria resulted in proteins displaying the binding centration of glutamate was maximal at glycine concen-
trations between 1±10 mM, whereas saturation of thepharmacology of AMPA and kainate receptors (Kuusi-
nen et al., 1995; Arvola and KeinaÈ nen, 1996). glutamate response in the presence of glycine occurred
at 10±100 mM; the corresponding concentrations forIn this study, we have analyzed these homology re-
gions in the NR2B subunit by substituting residues cor- half-maximal activation (EC50) were 0.54 and 1.5 mM,
respectively (Table 1). A significant difference in gluta-responding to positions mediating glycine binding to
the NR1 protein, and we show that they are crucial for mate affinity was found for two substitutions (NR2BE387A
and NR2BF390S) corresponding to the most N-terminalglutamate activation of the NMDA receptor. Our data
reveal positional identity of the determinants of gluta- glycine-binding residues of the NR1 subunit (Kuryatov et
al., 1994).Whereas the dose-response curves for glycinemate binding to the NR2B subunit and those of glycine
binding to the NR1 protein. Molecular modeling of the showed EC50 values similar to that of the wild-type re-
ceptor, the EC50 values for glutamate were increasedrespective domains of the NR1 and NR2B subunits into
the known coordinates of the bacterial leucine±arginine± about 240-fold for NR2BE387A and 50-fold for NR2BF390S,
respectively (Figures 2 and 3). Maximal current flow (Imax)ornithine binding protein (LAOBP) from Salmonella ty-
phimurium (Oh et al.,1993) provides structures that shed was not impaired in the NR2BE387A mutant but was re-
duced about 10-fold in mutant NR2BF390S (Table 1). Theselight on the pharmacological specificity of agonist and
antagonist binding to the NMDA receptor. Our data cre- data are consistent with the NR2B subunit having a
crucial role in glutamate binding.ate an experimental basis for rationalizing the design of
novel NMDA receptor ligands, which could serve as To further delineate contributions of the NR2B subunit
to the glutamate binding site of the NMDA receptor,therapeutic tools for preventing excitotoxic NMDA re-
ceptor activation in different acute and chronic neurode- another set of substitutions was analyzed. First, we mu-
tated the basic residues K459 and H460 (Figure 1); thesegenerative disorders.
amino acids correspond to a conserved motif in the
ligand binding site of glutamate receptors, including theResults
NR1 subunit (Kuryatov et al., 1994; Wafford et al., 1995),
the GluR1 subunit (Uchino et al., 1992), and the chickMajor Determinants of Glutamate Binding Are
Localized in the N-Terminal Extracellular kainate binding protein (Paas et al., 1996a). Introduction
of a negatively charged glutamate side chain in mutantDomain of the NR2B Subunit
To determine whether amino acid residues within NR2 NR2BK459E resulted in a 180-fold increased EC50 value for
glutamate (Figures 2 and 3 and Table 1) but had nosubunits are involved in ligand binding, we introduced
substitutions into the NR2B subunit at positions homolo- significant effect on glycine affinity. Similarly, substitu-
tion of the neighboring histidine residue by phenylala-gous to those in the NR1 protein that are known to
be important for glycine binding (Kuryatov et al., 1994; nine in mutant NR2BH460F caused a selective decrease in
glutamate affinity withoutchanging the glycine responseWafford et al., 1995; Hirai et al., 1996). The mutated
residues are localized in the two domains of the NR2 (Table 1). A third region contributing to glutamate bind-
ing was identified in a region preceding segment M1.polypeptide that show sequence and structural homol-
ogy with periplasmic bacterial amino acid±binding pro- Coexpression of mutant NR2BS486A with the NR1 subunit
generated NMDA receptors that displayed an EC50 valueteins, in particular LAOBP (O'Hara et al., 1993), e.g., the
domain preceding membrane segment M1 and the loop for glutamate of 65 mM, without a detectable change in
apparent glycine affinity (Figure 3). Isofunctional re-between membrane segments M3 and M4 (Figure 1).
This loop is known to be localized extracellularly in placement of an arginine residue (NR2BR493K) within the
Glutamate Binding Site of the NMDA Receptor
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Figure 2. Agonist Response Properties of
Wild-Type and Mutant NR2B Subunits
In vitro transcribed wild-type or mutant NR2B
subunit cRNAs were coinjected with the NR1
subunit cRNA into defolliculated Xenopus oo-
cytes. Membrane currents elicited by su-
perfusion of increasing concentrations of glu-
tamate in the presence of 10 mM glycine (left)
or of increasing concentrations of glycine in
the presence of 0.1±1 mM glutamate (right)
were recorded 2±6 days after injection.
Traces obtained with the wild-type NR2B
subunit (A), mutant NR2BE387A (B), and mutant
NR2BK459E (C) are shown.
same region resulted in a complete loss of the agonist region of sequence homology between NMDA receptor
subunits and LAOBP similarly affected the apparent af-response (Table 1). In conclusion, residues close to
membrane segment M1 of the NR2B subunit seem to finity of glutamate: mutant NR2BV709A displayed a 30-fold
increased EC50 value for glutamate activation (Figure 3).be important for glutamate binding to and/or channel
function of the NMDA receptor. None of these mutants showed a significant change in
the EC50 value of glycine (Table 1). Substitution of F731,
a residue homologous to F735 in the C-terminal part ofThe M3±M4 Loop Region of the NR2B Subunit
Contributes to Glutamate Binding the M3±M4 loop of the NR1 subunit (Hirai et al., 1996),
in mutant NR2BF731A failed to alter the glutamate re-In the NR1 subunit, proximal and distal residues of the
extracellular M3±M4 loop are known to contribute to sponse of the receptor; however, similar to the results
obtained with NR2BF390A, a significant reduction in maxi-coagonist potentiation of the NMDA receptor (Kuryatov
et al., 1994; Hirai et al., 1996). Therefore, agonist dose- mal current was observed (Table 1).
response curves were established for mutants NR2BV660A
and NR2BS664G. These mutations are located in a region Glutamate Antagonist Sensitivity
of the NR2B Mutantshomologous to the proximal portion of the glycine bind-
ing domain in the M3±M4 loop region of the NR1 subunit The data reported above indicate that major determi-
nants of glutamate binding are localized on the NR2B(Figure 1). Replacement of V660 by alanine resulted in
an ≈20-fold increase in the EC50 value for glutamate, subunit. To corroborate this finding further, we investi-
gated whether the substitutions introduced affected thewhereas substitution of S664 increased the latter .100-
fold (Figure 3 and Table 1). A substitution in a distal potency of specific glutamate antagonists. To this end,
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Table 1. Glutamate and Glycine Response Properties
of the NR2B Mutants
EC50 [mM]
L-Glutamate Glycine Imax [mA] n
NR2B 1.5 6 0.6 (1.6) 0.54 6 0.27 (1.7) 3.8 6 1.2 8
E387A 355 6 74* (1.5) 0.82 6 0.37 (1.5) 3.1 6 0.5 6
F390S 71 6 23* (1.5) 0.91 6 0.42 (1.5) 0.31 6 0.18 8
K459E 270 6 68* (1.4) 0.28 6 0.13 (1.7) 3.1 6 0.9 7
H460F 13 6 6.3* (1.1) 0.33 6 0.24 (1.8) 4.2 6 0.7 6
S486A 65 6 17* (1.4) 0.51 6 0.31 (1.5) 3.7 6 1.6 10
R493K NF NF 0 20
V660A 27 6 8.2* (1.5) 0.79 6 0.26 (1.7) 1.3 6 0.6 8
S664G 177 6 64* (1.2) 0.82 6 0.38 (1.7) 2.2 6 1.0 9
V709A 41 6 16* (1.7) 1.0 6 0.1 (1.8) 3.3 6 1.3 8
F731A 1.1 6 0.3 (1.4) 1.3 6 0.2* (1.2) 0.74 6 0.36 4
Wild-type and mutant NR2B cRNAs were coinjected with the NR1a
cRNA into Xenopus oocytes, and the receptors generated were
analyzed by voltage-clamp recording as detailed under Experimen-
tal Procedures. EC50 values 6 SD were calculated from dose-
response curves obtained from 3±9 oocytes; therespective Hill coef-
ficients (nH) are given in brackets. Nonfunctional mutants were tested
in $20 oocytes. Imax values were determined in the presence of
saturating concentrations of L-glutamate and glycine, respectively.
EC50 values marked by an asterisk were significantly different (p ,
0.01) from those of the wild-type receptor. NF, nonfunctional; n,
number of experiments.
inhibition curves were established at glutamate concen-
trations corresponding to the EC50 values of the respec-
tive NR2B mutants in the presence of saturating glycine
concentrations (Figure 4). Half-maximal inhibition was
seen for the phosphonic acid derivative D-(-)-2-amino-
5-phosphonopentanoic acid (D-AP5) at a concentration
of ≈4.7 mM with the wild-type NR2B subunit (Table 2).
A 40-fold increase in the concentration required for half-
maximal inhibition (IC50) was obtained with mutant
NR2BK459E,where an IC50 value of 190 mM was determined
(Figure 4). Simultaneously, the sensitivity for a another
related antagonist, 3-((R)-2-carboxypiperazin-4-yl)-pro-
pyl-1-phosphonic acid (R-CPP), was reduced 8-fold for
the same mutation (Table 2). In addition, significant re-
Figure 3. Agonist Dose-Response Curves of Wild-Type and Mutantductions in D-AP5 inhibition were obtained for mutants
NR2B SubunitsNR2BS486A, NR2BS664G and NR2BV709A (Figure 4 and Table
Dose-response curves for glutamate in the presence of saturating2). Thus, common binding determinants are shared by
concentrations of glycine (A) and for glycine in the presence ofagonists and antagonists of the glutamate site of the
saturating concentrations of glutamate (B) were determined for theNMDA receptor.
wild-type NR2B (closed circles) and the mutant NR2BE387A (open
triangles), NR2BK459E (closed triangles), NR2BS486A (closed squares),
Molecular Modeling of the Glutamate NR2BS664G (open squares), and NR2BV709A (open circles) subunits. For
EC50 values and Hill coefficients, see Table 1.and Glycine Binding Sites
The mutational analysis presented above shows that
substitutions in NR2B at positions homologous to the
glycine binding residues of the NR1 subunit increase N-terminal homology segments and most of the M3±M4
sequence could be adequately fitted into the knownthe concentrations of glutamate, but not glycine, re-
quired for NMDAreceptor channel gating. This is consis- coordinates of lobes I and II of LAOBP (Oh et al., 1993).
However, to conserve three a-helical regions character-tent with a conserved architecture of the agonist binding
folds formed by the NR1 and NR2 subunits. Based on istic of LAOBP's amino acid±binding site, a slightly mod-
ified version (see Figure 1) of previous alignments of thehomology considerations, we previously proposed a bi-
lobate structure of the glycine binding site of the NR1 NR2B and NR1 sequences with LAOBP (Monyer et al.,
1992; Kuryatov et al., 1994; Hirai et al., 1996) had to besubunit that used the known crystal structure of LAOBP
as a template (Kuryatov et al., 1994; Hirai et al., 1996). used. It should be emphasized that our binding site
models represent the liganded states of these proteinsHere, we evaluated our data from mutational analysis
further by modeling the glutamate and glycine binding before closure according to the ªVenus' flytrapº model.
We choose to model these states because they are likelysites of the NMDA receptor at high resolution. The
Glutamate Binding Site of the NMDA Receptor
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residues on lobe II may appear more distant in our mod-
els than predicted for the closed ligated proteins.
The Glutamate Binding Pocket
of the NR2B Subunit
The surface structure of the region of NR2B harboring
the glutamate binding fold is displayed in Figure 5A.
The predicted agonist binding site resides within a cleft
formed by the twohomology regionsthat can accommo-
date ligands larger than glutamate. Modeling of gluta-
mate into this pocket revealed that an optimal orienta-
tion of L-glutamate can beachieved when the a-carboxyl
group of the ligand is allowed to interact with R493 and
T488 (Figure 5B). The a-amino group of the ligand then
is hydrogen bonded to E387 and the backbone carbonyl
group of S486 (Figure 5B). These two residues contrib-
ute to a ring of hydrophilic amino acids (including E387,
H460, S486,T488, and R493)at the bottom of the binding
pocket that overlie a layer of hydrophobic side chains
(Figure 5B). The g-carboxyl group of glutamate is pre-
dicted to lie in the vicinity of, but not in direct contact
with, two regions of the receptor surface that contain
Figure 4. Inhibition of NR2B Wild-Type and Mutant Glutamate Re- charged residues, e.g., K463 adjacent to residue E492
sponses by D-AP5 (Figure 5B), and N490 adjacent to R667 (not shown).
Antagonist dose-response curves obtained with oocytes injected Assuming that K463 and R667 are in the protonated
with wild-type NR2B (closed circles), NR2BE387A (open triangles), state, these residues may form the center of an electron-
NR2BK459E (closed trianges), NR2BS486A (closed squares), NR2BS664G
deficient patch that attracts the g-carboxyl group of(open squares), and NR2BV709A (open circles) cRNAs are shown. The
glutamate (Figure 5A). S664 lies at the upper edge ofglycine concentrations used were 10 mM for the wild-type and the
this electron-deficient patch and may contribute to themutated NR2B subunits. Glutamate was used at concentrations
eliciting a half-maximal response as determined (Table 1). Data are stabilization of the positively charged residues K463 and
plotted as a fraction of the current observed in the absence of R667 (not shown) via the g-carboxyl group of the ligand
antagonist. For IC50 values, see Table 2. (Figure 5B). In accordance with our findings, substitution
of this residue should disrupt the polar surface in this
region of the binding pocket (see Figure 5A) and thusto represent the conformations from which the reactions
lower glutamate affinity. Since S664 is part of the upperleading to channel opening are initiated and thus are
surface of the ªVenus' flytrapº-like structure, a tightermost relevant to NMDA receptor pharmacology. Recep-
interaction between S664 and the agonist may occurtor±ligand interactions were modeled employing these
upon closure of the binding pocket. Another critical ly-ªopenº binding site configurations by using uncon-
sine residue, K459, is situated at its lower left edgestrained minimization. As a consequence, interacting
(behind the amino group of glutamate in our projection;
therefore not shown); mutation NR2BK459E drastically low-
Table 2. Inhibition of Current Responses by Glutamate ered the EC50 value of glutamate. Our model indicates
Antagonists that the charged side chain of K459 interacts with E386
IC50 [mM] and E417, thus stabilizing the electron-rich portion of
the agonist binding pocket without directly interactingR-CPP D-AP5
with the ligand. This stabilization is disrupted upon intro-
NR2B 0.92 6 0.36 (4) 4.7 6 1.3 (4) ducing a side chain of opposite charge.
E387A 0.83 6 0.24 (6) 1.5 6 0.6 (3)
To unravel features of L-glutamate that enable thisF390S 0.76 6 0.31 (3) 3.9 6 2.5 (3)
ligand to bind in an agonistic fashion, we also modeledK459E 7.8* 6 2.9 (3) 190* 6 24 (3)
the interaction with the antagonists tested above, D-AP5H460F 1.1 6 2.7 (5) 7.3 6 1.0 (3)
S486A 2.1* 6 0.3 (4) 8.7* 6 2.2 (5) (Figure 5C) and R-CPP (not shown). Both compounds
V660A 2.4 6 1.3 (5) 4.4 6 0.6 (3) represent elongated analogs of glutamate, in which the
S664G 1.2 6 0.5 (6) 11* 6 2.4 (3) g-carboxyl group is replaced by a phosphonic acid moi-
V709A 0.69 6 0.31 (3) 28* 6 12 (3)
ety. While such acids may be in equilibrium with theF731A 1.9 6 0.4 (3) 7.4 6 3.6 (3)
monoanionic form, we chose the fully ionized species for
Wild-type or mutant NR2B subunits were coexpressed with the modeling in order to simplify the search of conformation
NR1a polypeptide, andcurrent responses were analyzed by voltage- space available for each ligand. Additionally, the second
clamp recording as detailed under Experimental Procedures. IC50 nitrogen atom of R-CPP was evaluated in a protonatedvalues were determined at the EC50 value of L-glutamate in the
state. The resulting ligand±receptor models predict thatpresence of saturating concentrations of glycine for 3±6 oocytes
the a-aminocarboxylic acid portions of the antagonistseach. The Hill coefficients for R-CPP and D-AP5 inactivation were
nH 5 1.0±1.4 and 1.0±1.2, respectively, for the wild-type NR2B sub- adopt an orientation similar to that of L-glutamate. The
unit and all mutants tested. Values indicated by stars are signifi- a-carboxyl group is hydrogen bonded between T488
cantly different from wild-type (p 5 0.01). Numbers in brackets (n) and R493, while the adjacent protonated nitrogen center
indicate the number of experiments performed.
is stabilized by E387 (shown for D-AP5 in Figure 5C).
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Figure 5. Models of the Glutamate and Glycine Binding Sites of the NMDA Receptor
(A) Electron density surface and ribbon representation of the vicinity of the binding pocket of the NR2B subunit ligated with glutamate. The
structure of glutamate is displayed as a stick model. The peptide backbone is indicated by a white ribbon. Carbon atoms are shown in gray,
oxygen in red, nitrogen in blue, and hydrogen in white. Note electron-deficient surface (in red) of the region of the binding pocket underlying
glutamate's g-carboxyl group; blue regions represent areas of high electron density.
(B) Close-up view of the binding pocket of the NR2B subunit ligated with glutamate. Binding residues identified by site-directed mutagenesis
are shown in bold letters, whereas residues predicted to contribute to ligand binding by molecular modeling are indicated in plain text.
Predicted side chain interactions of glutamate are indicated by dashed lines. The a-amino group of glutamate is hydrogen bonded to E387
and the backbone carbonyl group of S486; the a-carboxyl group interacts with R493 and T488. The g-carboxyl group of glutamate forms a
salt bridge with R493 and can interact with K463 and R667 (not shown), which binds to S664.
(C) Structure of the NR2B binding pocket, ligated with D-AP5. The a-aminocarboxylic acid portion of the antagonist is ligated similarly as that
of glutamate in (B). The phosphonic acid head group closely interacts with U463. (The viewing angle of this display differs slightly from that
in [B] in order to improve visualization of the bound antagonist.)
(D) Model of the binding pocket of the NR1 subunit ligated with glycine. Note that the overall structure of the binding pocket and the
arrangement of binding residues are very similar to those of NR2B (B). The carboxyl group of glycine interacts with R505 and T500, whereas
the amino group is hydrogen bonded to Q387 (and the backbone carbonyl group of P498; not shown).
Owing to the greater side chain lengths of these ligands, appears to stabilize the amino group of the bound ligand
and R505. The upper region of the binding pocket con-the terminal phosphonic acid groups can directly hydro-
gen bond to K463 without perturbing the side chain tains a series of tryptophan and histidine residues (Fig-
ure 5D and not shown). The aromatic residues F390 andgeometry of this residue (Figure 5C).
The Glycine Binding Pocket of the NR1 Subunit W713 may form some type of zipper along one end
of the pocket structure, which could participate in theThe structure of the glycine binding pocket obtained
by identical procedures through modeling of the NR1 opening and closing of the binding fold similar to that
of LAOBP (Oh et al.,1993). Mutation of F390 may preventhomology regions shares many features with that of the
glutamate binding site. Again, an arginine residue (R505) the underlying conformational transition and thus ex-
plain the effects of respective substitutions on glycinetogether with a threonine (T500) ligates the carboxyl
group of glycine (Figure 5D). T500 is embedded in a coagonism (Kuryatov et al., 1994).
We also examined the binding of glycine site antago-sequence (positions 497±502) similar to that described
above for the NR2B subunit, which is predicted to form nists into the binding pocket of the NR1 subunit (data
not shown). Both 7-chlorokynurenate and its extendeda loop prior to the third helical region and to line the
bottom of the binding pocket (not shown). Consistent high affinity derivative, L701,324, were chosen as repre-
sentative competitive inhibitors of this site (Kemp andwith our mutagenesis data, the amino group of glycine
is hydrogen bonded to Q387 (Figure 5D) and to the Leeson, 1993). The electron-rich 2-quinolone carbonyl
unit of both ligands appeared to interact with R505,backbone carbonyl group of P498 (not shown). F466
Glutamate Binding Site of the NMDA Receptor
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while the chloroaromatic ring filled the left side of the questioning the functional relevance of this site (Laurie
und Seeburg, 1994). Pharmacologically specific high af-binding pocket, where it may be involved in p-electron
interactions with the numerous aromatic residues that finity binding of glutamate and NMDA has, however,
recently been demonstrated to the singly expressedoccupy this side of the NR1 binding pocket, in particular
F466. Interestingly, the phenoxyphenyl side chain of NR2A subunit, confirming that NR2 proteins are suffi-
cient to form a proper glutamate binding site (KendrickL701,324 seemed to stabilize both R505 and also the
distant R737 (Figure 5D). The latter residue is close to et al., 1996). In conclusion, these and our mutagenesis
data are consistent with the glycine and glutamate bind-a pair of phenylalanines (F735 and F736, not shown),
which are crucial for glycine activation of the NMDA ing sites residing on different subunits of the NMDA
receptor, the NR1 and the NR2 proteins, respectively.receptor (Hirai et al., 1996).
In conclusion, although the sequences of the gluta- Allosteric interactions between these subunits may ex-
plain the differences observed in glycine binding affin-mate and glycine binding sites differ by residue changes
that imply differential adjustments of backbone resi- ities when coexpressing the NR1 with different NR2 sub-
unit isoforms (Monyer et al., 1992; Kendrick et al., 1996).dues, both agonist binding pockets appear to be re-
markably similar in their overall structures despite their Our data on mutant NR2B subunit expression support
a strict segregation of the glutamate and glycine bindingrather differently sized ligands. Apart from individual
side chain substitutions, major structural differences sites to the different NMDA receptor polypeptides. Sub-
stitution of NR2B residues in the region preceding mem-seem to involve the presence of more bulky aromatic
residues in the amino group binding region of the NR1 brane segment M1 and the loop domain separating
membrane segments M3 and M4 caused drastic de-pocket, compared to the NR2 glutamate binding site.
creases in the apparent affinity for glutamate without
significantly changing the glycine response. Inversely,
Discussion mutation of the corresponding regions of the NR1 sub-
unit has been shown to strongly reduce the potency of
The data presented in this study indicate that major glycine, but not of glutamate, in channel gating (Kurya-
determinants of glutamate binding to the NMDA recep- tov et al., 1994; Hirai et al., 1996). Since two molecules
tor reside in the extracellular domains of NR2 subunits. of glutamate and glycine each are thought to be required
Although our experiments focused on the NR2B poly- for channel activation (Benveniste and Mayer, 1991;
peptide, it should be emphasized that the binding resi- Clements and Westbrook, 1991), this implies that the
dues identified here are strictly conserved in all NR2 NMDA receptor should be composed of at least four
subunits. The location of the glutamate binding site on subunits. Indeed, recent data from our laboratory sug-
the NR2 subunits is surprising in view of the initial isola- gest that heteromeric NR1±NR2B receptors have a tetra-
tion of the NR1 subunit cDNA by expression cloning in meric structure (B. L., J. K., and H. B., unpublished data).
Xenopus laevis oocytes of channels that are coopera- In both subunits, the mutated regions display significant
tively gated by glutamate and glycine (Moriyoshi et al., sequence and structural homology to bacterial amino
1991). Furthermore, different studies have reported the acid±binding proteins, indicating the conservation of an
formation of functional NMDA receptors upon injection ancestral amino acid±binding foldwithin NMDA receptor
of NR1 cRNA into oocytes (Durand et al., 1992; Hollmann polypeptides (O'Hara et al., 1993). Using this sequence
et al., 1993; Zheng et al., 1994). However, these homo- homology and the known three-dimensional structure of
meric receptors form only with low efficiency and display LAOBP, we modeled the glutamate and glycine binding
unusual properties not detectable in native receptors, sites of the NR2B and NR1 subunits, respectively, at
like a potentiation by micromolar concentrations of Zn21 high resolution. Our models reveal that both agonist
(Hollmann et al.,1993) and a resistance to redox modula- binding sites are rather similar in their overall structures
tion (Sullivan etal., 1994). Furthermore, expression of the but differ in some crucial side chains and size of aro-
NR1 subunit cDNA alone does not generate glutamate- matic residues. The arrangement of these substitutions
gated ion channels in mammalian cell lines; here, coex- provides an explanation for the high selectivity of ago-
pression of the NR1 with an NR2 subunit is essential for nist and antagonist binding by these subunits.
obtaining functional NMDA receptors (Grimwood et al., The most significant changes of apparent glutamate
1995; Priestley et al., 1995; McIlhinney et al., 1996). This affinities were obtained with mutations within three short
suggests that Xenopus oocytes may contain proteins, sequence regions of the NR2B subunit. In particular,
e.g., chaperones or endogenous NR2-like subunits, substitution of E387, K459, and S664 resulted in a 100
which are essential for the assembly of functional re- to .200-fold decrease of glutamate affinity. Our model
combinant NMDA receptors. Radioligand binding stud- of the glutamate binding site predicts that replacement
ies with mammalian cells expressing the NR1 subunit of E387 by alanine causes a loss of the ionic interaction
have confirmed the presence of a high affinity glycine with the agonist's a-amino group. In contrast, K459 does
binding site on this polypeptide, whereas neither NMDA not appear to interact directly with bound glutamate but
nor the competitive glutamate antagonist [3H]CGP- might have a crucial role in stabilizing the ligand binding
39653 bound under the same conditions (Laurie and pocket. R493 seems to be particularly important for glu-
Seeburg, 1994; Lynch et al., 1994; Grimwood et al., 1995; tamate binding since replacement of this residue in the
Kawamoto et al., 1995). In one report, high affinity NR2B subunit by an isofunctional lysine residue resulted
[3H]glutamate binding to the NR1 subunit expressed in in the formation of a nonfunctional receptor. A similar
HEK 293 cells has been detected; however, this binding result has previously been obtained upon mutation of
the homologous positions in the NR1 subunit (Hirai etresisted displacement by NMDA or antagonists, thus
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al., 1996) and the GluR1 polypeptide (Uchino et al., to indicate that for efficient agonistic binding, the two
ends of glutamate must be bound by the receptor sur-1992). Our homology-based modeling of the NR2B and
NR1 binding folds reveals that this conserved arginine face. This may be attained by a conformational change
within the receptor pocket, which reduces the distanceextends its side chain from a highly conserved helix
directly toward the ligand. Thus, inanalogy to the homol- between the two binding motifs identified in this study.
We propose that this conformational change is only in-ogous R77 of LAOBP (Oh et al., 1993), the guanidinium
groups of R493 in the NR2B subunit and of R505 in duced by agonists. Conversely, a simple antagonist acts
by blocking the binding motifs without altering their dis-the NR1 subunit interact ionically with the a-carboxyl
groups of glutamate and glycine, respectively. tance. Accordingly, activation of the ion channel com-
plex results from an allosteric motion of the subunitsIn contrast to these highly conserved structures ligat-
ing the a-aminocarboxylic acid portion of the agonists, initiated by contraction of the distance between the two
regions of the binding fold that interact strongly withthe residues contacting the agonist side chains diverge
between NR1 and NR2. In particular, the positively L-glutamate. The highly provocative positioning of K463
close to the exterior of the binding pocket and its chargecharged ring system of H460 in the NR2B subunit ap-
pears to be crucial for the high affinity binding of gluta- pairing with the surface-exposed acidic side chain of
E492 suggest that these residues may be crucial inmate. In the NR1 subunit, the residue equivalent to H460
corresponds to F466. This may reflect differences in the transmitting the ªsignalº of glutamate binding to the
surface of the individual NR2B subunit, thus triggeringhydrophilic nature of the agonist side chains and the
residues at position 387 (glutamate in NR2B versus glu- opening of the oligomeric ion channel complex. Specifi-
cally, a relocation of K463 toward the g-carboxyl grouptamine in NR1, respectively). While both of the latter
residues could act as p-electron donors for stabilization of the bound agonist may initiate the chain of conforma-
tional transitions that finally induce the gating process.to the ligand's protonated a-amino group, the additional
hydrophilicity of the histidine ring might provide further An experimental examination of this gating model is in
progress in our laboratory.stabilization of the more polar NR2B binding pocket.
Replacement of S664 by glycine resulted in a significant During the preparation of this manuscript, Paas et al.
(1996b) published a mutational analysis of the chickreduction of glutamate affinity; this is consistent with
the close apposition of this residue to the extended kainate binding protein, a truncated nonmammalian ho-
molog of glutamate receptor subunits of unknown func-side chain of glutamate. In contrast, mutation of the
homologous S670 of the NR1 subunit had no effect on tion. Using equilibrium radioligand binding, they identi-
fied several agonist and antagonist binding residues,glycine affinity, which agrees well with the considerable
distance between this residue and the bound agonist. most of which lie at positions homologous to those impli-
cated in glycine binding to the NR1 (Kuryatov et al.,Comparison of the models of NR2B ligated by the
competitive glutamate antagonists D-AP5 and R-CCP 1994; Hirai et al., 1996) and in glutamate binding to the
NR2B (this study) subunits. Consequently, the overallwith that of the glutamate-occupied binding site corrob-
orates the above-mentioned conclusions. The a-car- structure of the LAOBP-based model of the kainate
binding pocket presented by these authors shares sev-boxyl group of these phosphonic acid±based antago-
nists is predicted to be stabilized by T488 and R493, eral features with that of the NMDA receptor binding
sites discussed here. However, the model of Paas et al.while the protonated a-amino group forms a salt bridge
with E387. Although, in contrast to glutamate, both an- uses the closed rather than the open state of the bacte-
rial protein as a structural template, i.e., a conformationtagonists exhibit an R stereochemistry around the C2
center, the stabilization of this portion of all ligands is likely to correspond to a desensitized rather than an
activated receptor (Mano et al., 1996). Moreover, thehighly comparable. Thus, residues E387, F390, H460,
S486, and R493 form a common binding motif for the interaction of agonists with the chick kainate binding
protein differs significantly from that of glutamate witha-aminocarboxylic acid region of glutamate and its
structurally related antagonists. In contrast, the interac- the NR2B subunit in that only nonionic polar side chains
are suggested for ligand binding. Also, the conformationtions of the phosphonic acid side chains with the binding
pocket differ from that of glutamate. While the side chain proposed for glutamate and kainate within the binding
pocket of the chick kainate binding protein deviatesof L-glutamate isnot long enough to form a strong hydro-
gen bond with the positively charged head group of from that predicted here and that inferred frommedicinal
chemistry (Chamberlin and Bridges, 1993; ShimamotoK463, D-AP5 and R-CPP strongly interact with this ly-
sine. The longer side chains of these antagonists also and Ohfune, 1996). Further comparison of the structures
presented by Paas et al. (1996b) and in this study mightimply that the phosphonic acid groups are not in close
proximity to S664, which is consistent with the modest highlight features relevant for agonist discrimination and
the conformational transitions related to channel gatingeffect of the S664A mutation on antagonist affinity. In
conclusion, K463 and S664 appear to becrucial determi- and inactivation.
In conclusion, our data possibly provide the first de-nants of a second binding motif that is important for
agonist±antagonist discrimination. tailed molecular framework for understanding the gluta-
mate binding site of the NMDA receptor. In addition, theWhile our models predict that the interactions of
L-glutamate and phosphonic acid antagonists with the comparative modeling approach described here allows
predictions about the binding properties of its two prin-NR2B glutamate binding pocket are very similar, the
results of mutations within the a-aminocarboxylic acid cipal agonist binding sites. Further exploitation of our
models thus should foster the rational design of drugsbinding region (E387, F390S, K459E, and H460F) appear
to suggest the contrary. We interprete this discrepancy that selectively target these sites and allow modulation
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using standardalgorithms for predicting protein secondary structureof NMDA receptor channel activity under physio- and
(Fasman, 1989). Utilizing the predicted propensity of these frag-pathological conditions.
ments to adopt helical, b-sheet, or turn geometries, thesesequences
were modeled further by comparison to a protein structural library
Experimental Procedures and then annealed onto the existing structural framework. The com-
plete structure was energetically minimized by initially holding the
In Vitro Mutagenesis peptide backbone rigid (until root mean square difference ,0.01),
Mutations were introduced into the NR2B (or e2; see Kutsuwada et and then without constraints. The dielectric constant was set at 1.0;
al., 1992) subunit cDNA by polymerase chain reaction using the this value was found to be adequate to reduce reorganization of
following restriction fragments of plasmid pNR2B: 1.6 kb AflII/ClaI the protein backbone. Subsequently, the individual side chains were
for mutants E387A and F390S; 0.8 kb BstEII for mutants K459A and adjusted to remove unusual conformations, and the structure was
H460F; 0.82 kb SphI for mutants S486A, R493K, V660A, and S664G; again reminimized. Charged and polar side chains were manually
and 0.64 kb BsmI for mutants V709A and F731A. The redundancy adjusted to maximize pairing of H bonds and opposite charges
of the genetic code was exploited to design primers for each mutant followed by repeated minimization.
so as to introduce novel diagnostic restriction enzyme cleavage Modeling of Receptor±Ligand Complexes
sites in the vicinity of the substitution. The resulting mutant cas- Individual ligands were placed within close proximity (1±2 AÊ ) of the
settes were subcloned into the NR2B cDNA using the above-men- presumed binding pocket, and then the receptor±ligand complex
tioned restriction sites and confirmed by DNA sequencing. was energetically minimized without constraints. For each ligand,
its conformation and orientation within the binding pocket was sys-
cRNA Synthesis and Oocyte Expression tematically adjusted, and the complex was reminimized. Only the
NotI-linearized plasmid cDNAs were used for the in vitro synthesis lowest energy structure was retained after each iteration. This pro-
of cRNA (mCAP mRNA Capping Kit, Stratagene, San Diego, CA) cedure resulted in models that represent an optimal fit of the ligand
as described (Kuryatov et al., 1994). cRNAs of the rat clone pN60 within the respective binding pocket.
(containing the NR1a cDNA; see Moriyoshi et al., 1991) and the
mouse e2 plasmid (containing the NR2B cDNA, see Kutsuwada et Acknowledgments
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